• #ERDC2018 – New EU Law to Protect Patient Data Could Affect Rare Disease Registries
  • Vast Therapeutics’ Therapy Candidate BIOC51 Fares Well in Mouse Studies
  • #ATS2018 — Arrowhead’s Investigational CF Treatment ARO-ENaC Shows Potential in Preclinical Studies
  • #ECFS2018 — Celtaxsys Completes Phase 2b Trial Assessing Acebilustat in Cystic Fibrosis Patients
  • Medication Side Effects: Necessary Evils
  • Triclosan, Antibacterial in Toothpaste, Works Well as Combo Antibiotic Treatment, Study Suggests
  • #ECFS2018 – Disparities in CF Care Across Europe Focus of ECFS Meeting in Belgrade
  • #ECRD2018 – EU Must Do More for Rare Disease Patients, Eurordis Leaders Say
  • ‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
  • Long-term Kalydeco Treatment Improves Clinical Outcomes in Cystic Fibrosis Patients, Study Shows
  • 26 Years and Counting with CF
  • Once-daily Tobramycin Safe to Treat Flares in Children Under Age 6, Study Says